2022
Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States
Bewersdorf JP, Prozora S, Podoltsev NA, Shallis R, Huntington SF, Neparidze N, Wang R, Zeidan AM, Davidoff AJ. Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States. Blood Advances 2022, 6: 376-385. PMID: 34724703, PMCID: PMC8791583, DOI: 10.1182/bloodadvances.2021005642.Peer-Reviewed Original ResearchConceptsAcute promyelocytic leukemiaAdverse outcomesPromyelocytic leukemiaNational Comprehensive Cancer Network guidelinesBaseline white blood cell countFavorable long-term prognosisWhite blood cell countVizient Clinical Data BaseGuideline-concordant regimensGuideline-concordant therapyGuideline-concordant treatmentGuideline-recommended therapiesBaseline clinical characteristicsHigh-risk diseaseLong-term prognosisPopulation-based registryBlood cell countClinical data baseLarge database analysisLogistic regression modelsTreatment concordanceClinical characteristicsReal-world practiceTreatment patternsNetwork guidelines
2015
Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia
Perreault S, Moeller J, Patel K, Eyler R, Pham T, Russell K, Podoltsev N. Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia. Journal Of Oncology Pharmacy Practice 2015, 22: 646-651. PMID: 25972392, DOI: 10.1177/1078155215586235.Peer-Reviewed Original ResearchConceptsHemodialysis-dependent patientsAcute promyelocytic leukemiaArsenic trioxidePromyelocytic leukemiaPre-existing cardiac conditionsRelapsed acute promyelocytic leukemiaSevere renal impairmentFront-line treatmentPaucity of dataRenal impairmentDialysis patientsDose adjustmentHemodialysis patientsCardiac conditionsPatientsThree timesLeukemiaRegimenDialysisImpairmentMarginal amount